Management of the ACC/AHA Stage D Patient. Cardiac Transplantation

Cardiology Clinics

Volumn 32, Issue 1, 2014, Pages 95-112

  Kittleson, Michelle M ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiac transplantation; End stage heart failure; Immunosuppression; Rejection

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ATOVAQUONE; AZATHIOPRINE; BORTEZOMIB; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CLOTRIMAZOLE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; GASTROINTESTINAL AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ALOPECIA; ANGINA PECTORIS; ANTIBODY MEDIATED REJECTION; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CAREGIVER SUPPORT; CATARACT; CORONARY ARTERY BYPASS SURGERY; COUNTERPULSATION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELUTING STENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRACORPOREAL OXYGENATION; FATIGUE; FLUID RETENTION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAPEFRUIT; GRAPEFRUIT JUICE; HEART EJECTION FRACTION; HEART FAILURE; HEART INNERVATION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVASCULAR ULTRASOUND; KIDNEY DYSFUNCTION; LEUKOPENIA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MENTAL INSTABILITY; MOUTH ULCER; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PERCUTANEOUS CORONARY INTERVENTION; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRESSORECEPTOR; PRIORITY JOURNAL; PROGNOSIS; RETRANSPLANTATION; REVIEW; SIDE EFFECT; THRUSH; TOXOPLASMOSIS; TREATMENT CONTRAINDICATION; TREMOR; ULCER; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

CARDIAC TRANSPLANTATION; END-STAGE HEART FAILURE; IMMUNOSUPPRESSION; REJECTION;

ALLOGRAFTS; AZATHIOPRINE; CARDIOTONIC AGENTS; GRAFT OCCLUSION, VASCULAR; GRAFT REJECTION; HEART; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; MYCOPHENOLIC ACID; NEOPLASMS; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE CARE; STEROIDS;

EID: 84888302930     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2013.09.004     Document Type: Review

References (65)

1. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 10.1161/CIR.0b013e31829e8776.
2. Stehlik J., Edwards L.B., Kucheryavaya A.Y., et al. The registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. JHeart Lung Transplant 2012, 31(10):1052-1064. 10.1016/j.healun.2012.08.002.
3. Balady G.J., Arena R., Sietsema K., et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 2010, 122(2):191-225.
4. Mehra M.R., Kobashigawa J., Starling R., et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. JHeart Lung Transplant 2006, 25(9):1024-1042.
5. Gustafsson F., Ross H.J. Renal-sparing strategies in cardiac transplantation. Curr Opin Organ Transplant 2009, 14:566-570. 10.1097/MOT.0b013e32832e6f7b.
6. Lindenfeld J., Miller G.G., Shakar S.F., et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation 2004, 110(24):3734-3740.
7. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. NEngl J Med 2005, 352:2705-2713.
8. Lindenfeld J., Miller G.G., Shakar S.F., et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 2004, 110(25):3858-3865.
9. Kobashigawa J.A., Patel J., Furukawa H., et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. JHeart Lung Transplant 2006, 25(4):434-439.
10. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, 6(6):1377-1386.
11. Baran D.A., Zucker M.J., Arroyo L.H., et al. Aprospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the Tacrolimus in Combination, Tacrolimus Alone Compared (TICTAC) trial. Circ Heart Fail 2011, 4(2):129-137. 10.1161/circheartfailure.110.958520.
12. Eisen H.J., Kobashigawa J., Keogh A., et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. JHeart Lung Transplant 2005, 24(5):517-525.
13. Lehmkuhl H., Hummel M., Kobashigawa J., et al. Enteric-coated mycophenolate-sodium in heart transplantation: efficacy, safety, and pharmacokinetic compared with mycophenolate mofetil. Transplant Proc 2008, 40(4):953-955. 10.1016/j.transproceed.2008.03.046.
14. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004, 110(17):2694-2700.
15. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. NEngl J Med 2003, 349(9):847-858.
16. Eisen H.J., Kobashigawa J., Starling R.C., et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013, 13(5):1203-1216. 10.1111/ajt.12181.
17. Flechner S.M., Kobashigawa J., Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008, 22(1):1-15.
18. Stehlik J., Edwards L.B., Kucheryavaya A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report-2010. JHeart Lung Transplant 2010, 29(10):1089-1103.
19. Saraiva F., Matos V., Goncalves L., et al. Complications of endomyocardial biopsy in heart transplant patients: a retrospective study of 2117 consecutive procedures. Transplant Proc 2011, 43(5):1908-1912.
20. Baraldi-Junkins C., Levin H.R., Kasper E.K., et al. Complications of endomyocardial biopsy in heart transplant patients. JHeart Lung Transplant 1993, 12(1 Pt 1):63-67.
21. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. JHeart Lung Transplant 2005, 24(11):1710-1720.
22. Billingham M.E., Cary N.R., Hammond M.E., et al. Aworking formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. JHeart Transplant 1990, 9(6):587-593.
23. Kobashigawa J., Crespo-Leiro M.G., Ensminger S.M., et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. JHeart Lung Transplant 2011, 30(3):252-269.
24. Deng M.C., Eisen H.J., Mehra M.R., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006, 6(1):150-160.
25. Pham M.X., Teuteberg J.J., Kfoury A.G., et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. NEngl J Med 2010, 362(20):1890-1900.
26. Jarcho J.A. Fear of rejection-monitoring the heart-transplant recipient. NEngl J Med 2010, 362(20):1932-1933.
27. Mehra M.R., Parameshwar J. Gene expression profiling and cardiac allograft rejection monitoring: is IMAGE just a mirage?. JHeart Lung Transplant 2010, 29(6):599-602.
28. Kobashigawa J., Patel J., Kittleson M., et al. Results of a randomized trial of Allomap vs. heart biopsy in the first year after heart transplant: early invasive monitoring attenuation through gene expression trial. JHeart Lung Transplant 2013, 32(4):S203.
29. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108(1):48-53.
30. Kobashigawa J.A., Stevenson L.W., Moriguchi J.D., et al. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. JAm Coll Cardiol 1993, 21(5):1142-1144.
31. Wu G.W., Kobashigawa J.A., Fishbein M.C., et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. JHeart Lung Transplant 2009, 28(5):417-422.
32. Kfoury A.G., Stehlik J., Renlund D.G., et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. JHeart Lung Transplant 2006, 25(11):1277-1282.
33. Kfoury A.G., Hammond M.E., Snow G.L., et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. JHeart Lung Transplant 2009, 28(8):781-784.
34. Arbustini E., Roberts W.C. Morphological observations in the epicardial coronary arteries and their surroundings late after cardiac transplantation (allograft vascular disease). Am J Cardiol 1996, 78(7):814-820.
35. Fishbein M.C., Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol 2004, 19(2):166-169.
36. Kittleson M.M., Patel J.K., Moriguchi J.D., et al. Heart transplant recipients supported with extracorporeal membrane oxygenation: outcomes from a single-center experience. JHeart Lung Transplant 2011, 30(11):1250-1256.
37. Patel J.K., Kittleson M., Kobashigawa J.A. Cardiac allograft rejection. Surgeon 2011, 9(3):160-167.
38. Patel J., Everly M., Chang D., et al. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. JHeart Lung Transplant 2011, 30(12):1320-1326.
39. Kirklin J.K., Brown R.N., Huang S.T., et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. JHeart Lung Transplant 2006, 25(3):283-288.
40. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. JHeart Lung Transplant 1998, 17(8):744-753.
41. Syeda B., Roedler S., Schukro C., et al. Transplant coronary artery disease: incidence, progression and interventional revascularization. Int J Cardiol 2005, 104(3):269-274.
42. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. JAm Coll Cardiol 2005, 45(9):1532-1537.
43. Uretsky B.F., Kormos R.L., Zerbe T.R., et al. Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. JHeart Lung Transplant 1992, 11(3 Pt 2):S45-S51.
44. Potluri S.P., Mehra M.R., Uber P.A., et al. Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival in heart transplantation. JHeart Lung Transplant 2005, 24(8):1019-1025.
45. Aranda J.M., Hill J. Cardiac transplant vasculopathy. Chest 2000, 118(6):1792-1800.
46. Stark R.P., McGinn A.L., Wilson R.F. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. NEngl J Med 1991, 324(25):1791-1794.
47. Ramsdale D.B., Bellamy C.M. Angina and threatened acute myocardial infarction after cardiac transplantation. Am Heart J 1990, 119(5):1195-1197.
48. Schroeder J.S., Hunt S.A. Chest pain in heart-transplant recipients. NEngl J Med 1991, 324(25):1805-1807.
49. Gao S.Z., Schroeder J.S., Hunt S.A., et al. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol 1989, 64(18):1093-1097.
50. Kapadia S.R., Nissen S.E., Tuzcu E.M. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999, 14(2):140-150.
51. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation 1998, 98(24):2672-2678.
52. Rickenbacher P. Role of intravascular ultrasound versus angiography for diagnosis of graft vascular disease. Transplant Proc 1998, 30(3):891-892.
53. Konig A., Theisen K., Klauss V. Intravascular ultrasound for assessment of coronary allograft vasculopathy. ZKardiol 2000, 89(Suppl 9):IX/45-IX/49.
54. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. NEngl J Med 1995, 333(10):621-627.
55. Sharifi M., Siraj Y., O'Donnell J., et al. Coronary angioplasty and stenting in orthotopic heart transplants: a fruitful act or a futile attempt?. Angiology 2000, 51(10):809-815.
56. Tanaka K., Li H., Curran P.J., et al. Usefulness and safety of percutaneous coronary interventions for cardiac transplant vasculopathy. Am J Cardiol 2006, 97(8):1192-1197.
57. Simpson L., Lee E.K., Hott B.J., et al. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J Heart Lung Transplant 2005, 24(9):1211-1217.
58. Smith J.A., Ribakove G.H., Hunt S.A., et al. Heart retransplantation: the 25-year experience at a single institution. JHeart Lung Transplant 1995, 14(5):832-839.
59. Fishman J.A. Infection in solid-organ transplant recipients. NEngl J Med 2007, 357(25):2601-2614.
60. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003, 17(2):77-88.
61. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82(5):663-668.
62. Kobashigawa J.A., Kiyosaki K.K., Patel J.K., et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. JHeart Lung Transplant 2011, 29(5):504-508.
63. Mathew T., Kreis H., Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies*. Clin Transplant 2004, 18(4):446-449.
64. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. JAm Soc Nephrol 2006, 17:581-589.
65. Salgo R., Gossmann J., Schöfer H., et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010, 10(6):1385-1393.